Search Patents
  • Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
    Publication number: 20060110758
    Abstract: The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR.
    Type: Application
    Filed: October 28, 2005
    Publication date: May 25, 2006
    Inventors: Bojian Zheng, Yi Guan, Jiandong Huang, Ming-Liang He
  • Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
    Patent number: 7491489
    Abstract: The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: February 17, 2009
    Assignee: The University of Hong Knog
    Inventors: Bojian Zheng, Yi Guan, Jiandong Huang, Ming-Liang He
  • Methods for producing and using IgY antibodies targeting the middle east respiratory syndrome coronavirus spike protein to treat or prevent MERS-CoV infection
    Patent number: 11319382
    Abstract: Chicken egg yolk antibodies (IgY Abs) specific to the Middle Eastern Respiratory Syndrome coronavirus spike (MERS-CoV S) protein demonstrate efficacy against MERS-CoV infection. The S-specific IgY Abs (anti-S IgY) are produced by injecting chickens with purified a recombinant MERS-CoV S protein, S1 subunit, or an S1 fragment. The purified anti-S IgY specifically bind to the MERS-CoV S protein and inhibit infection. In vitro neutralization of the IgY Abs against MERS-CoV was achieved in cell lines and in a human-transgenic mouse model treated with a pharmaceutical composition comprising the anti-S IgY. Viral antigen-positive cells in treated mice were reduced, compared to the adjuvant-only controls. Moreover, lung cells of anti-S IgY-treated mice showed significantly reduced inflammation, compared to the controls. Efficient neutralization of MERS-CoV infection is demonstrated both in vitro and in vivo using the anti-S IgY Abs.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: May 3, 2022
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Esam Ibraheem Azhar, Sherif Ali El-Kafrawy, Aymn Talat Abbas, Ashraf Abdu Tabil
  • METHOD AND PLATFORM FOR ENHANCING DETECTION ACTIVITY OF INTERACTION BETWEEN SPIKE PROTEIN RECEPTOR BINDING DOMAIN OF CORONAVIRUS FROM SPECIMEN AND HUMAN ANGIOTENSIN-CONVERTING ENZYME II
    Publication number: 20220412959
    Abstract: The present disclosure provides a method and a platform for enhancing detection activity of an interaction between a spike protein receptor binding domain of coronavirus from a specimen and a human angiotensin-converting enzyme II. The method and the platform of the present disclosure use a cleavable luciferase as a report test for the combination of the spike protein receptor binding domain of coronavirus (such as novel coronavirus) and angiotensin-converting enzyme II. Screening is carried out at the cellular level. The strength of the drug's influence on the interaction between the two molecules can be judged by the strength of the luminescence signal. The detection time can be completed within 20 minutes.
    Type: Application
    Filed: October 19, 2021
    Publication date: December 29, 2022
    Inventors: Hui-Ching Wang, Tian-Neng Li
  • STABLE CORONAVIRUS PROTEINS AND VACCINE COMPOSITIONS THEREOF
    Publication number: 20220325279
    Abstract: Provided herein are compositions and methods comprising mutated coronavirus “S” spike proteins or receptor binding domains thereof that have an increased expression level, yield and stability compared to its corresponding native or wild-type coronavirus spike protein under the same expression, culture or storage conditions. These mutated spike proteins can be used for generating a protein-based vaccine against one or more coronaviruses.
    Type: Application
    Filed: December 28, 2021
    Publication date: October 13, 2022
    Applicants: UNIVERSITY OF WASHINGTON, FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Daniel ELLIS, Neil KING, Jesse BLOOM, Tyler STARR, Allison GREANEY
  • Coronavirus Spike Glycoprotein With Improved Expression and Stability
    Publication number: 20230398204
    Abstract: The present invention includes a mutant coronavirus spike protein, methods of making and using, vaccines, vectors and nucleic acids, comprising at least one of the following modifications: a short flexible peptide linker or a rigid peptide linker in place of the furin cleavage site loop to genetically link an 51 and S2 subunit; at least one additional disulfide bond; or 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the resulting mutant coronavirus spike protein has at least one of: a higher stability or a higher level of expression when compared to a non-modified coronavirus spike protein. In one example, the coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, or an emerging variant thereof. Current SARS-CoV-2 variants include, e.g., B.1.1.7, B.1.1.7 with E484K, B.1.135, B.1.351, P.1, B.1.427, D614G, B.1.1351, or B.1.429, Lambda (i.e., C.37), Mu (i.e. B.1.621), and others.
    Type: Application
    Filed: October 21, 2020
    Publication date: December 14, 2023
    Inventors: Erica Ollman Saphire, Eduardo Olmedillas, Colin Mann
  • BINDING AGENTS FOR CORONAVIRUS S PROTEIN
    Publication number: 20230287088
    Abstract: The present disclosure relates to a binding agent comprising a first and a second binding domain, wherein the first binding domain is capable of binding to a coronavirus spike protein (S protein) and the second binding domain is capable of binding to the coronavirus S protein, and wherein the first and second binding domains bind to different epitopes of the coronavirus S protein. Moreover, the disclosure relates to an antibody capable of binding to a coronavirus spike protein (S protein). The disclosure also relates to a nucleic acid such as RNA encoding the binding agent, in particular antibody, disclosed herein and a host cell transformed or transfected with said nucleic acid. Furthermore, the disclosure relates to a medical use of said binding agent, antibody, or nucleic acid. The agents and medical uses described herein are, in particular, useful for the prevention or treatment of coronavirus infection in a subject.
    Type: Application
    Filed: July 29, 2021
    Publication date: September 14, 2023
    Inventors: Karsten Beckmann, Anna Carle, Sandra Prassl, Claudia Paulmann, Christiane Stadler, Georg Falck, Leyla Fischer, Alexander Muik, Ugur Sahin, Caroline Scharf
  • Canine Respiratory Coronavirus (Crcv) Spike Protein, Polymerase and Hemagglutinin/Esterase
    Publication number: 20070248616
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g. Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14).
    Type: Application
    Filed: July 1, 2003
    Publication date: October 25, 2007
    Inventors: John Brownlie, Victoria Chalker, Kerstin Erles
  • ANTIBODIES TARGETING THE SPIKE PROTEIN OF CORONAVIRUSES
    Publication number: 20240117011
    Abstract: Disclosed are monoclonal antibodies, antigen binding fragments, and bi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies.
    Type: Application
    Filed: February 4, 2022
    Publication date: April 11, 2024
    Applicant: The U.S.A., as Represented by the Secretary, Department of Health and Human Services
    Inventors: John Misasi, Lingshu Wang, Chaim Aryeh Schramm, John R. Mascola, Daniel Cesar Douek, Nancy J. Sullivan, Amy Ransier Henry, Tongqing Zhou, Peter D. Kwong, Wei Shi, Yi Zhang, Eun Sung Yang, Mario Roederer, Rosemarie Diana Mason, Amarendra Pegu, Julie E. Ledgerwood
  • ANTIBODIES TO CORONAVIRUS SPIKE PROTEIN AND METHODS OF USE THEREOF
    Publication number: 20230399384
    Abstract: Provided herein are antibodies binding to Coronavirus S protein and the uses of the antibodies in detecting and treating Coronavirus infection, such as COVID-19.
    Type: Application
    Filed: April 22, 2021
    Publication date: December 14, 2023
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zhiqiang KU, Ningyan ZHANG, Zhiqiang AN, Xuping XIE, Pei-Yong SHI
  • Canine respiratory coronavirus (CRCV) spike protein, polymerase and hemagglutinin/esterase
    Patent number: 7776340
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (eg Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14).
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: August 17, 2010
    Assignee: The Royal Veterinary College
    Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
  • Immunogenic Coronavirus Fusion Proteins and Related Methods
    Publication number: 20230399364
    Abstract: Provided are fusion proteins including an amino acid sequence of an ectodomain of Spike protein of a coronavirus, such as SARS-CoV-2, joined to an amino acid sequence of a ferritin subunit polypeptide. Nanoparticles including such fusion proteins, with surface-exposed trimers of the ectodomain of the Spike protein of the coronavirus, are also provided. Also provided are nucleic acids and vectors encoding the fusion proteins, cells containing such nucleic acid and vectors, immunogenic compositions including the fusion proteins, the nanoparticles, or the vectors, as well as corresponding methods and kits.
    Type: Application
    Filed: August 27, 2021
    Publication date: December 14, 2023
    Applicants: The Board of Trustees of the Leland Stanford Junior University, CZ Biohub SF, LLC
    Inventors: Abigail E. Powell, Payton Anders-Benner Weidenbacher, Natalia Friedland, Mrinmoy Sanyal, Peter S. Kim
  • CORONAVIRUS VACCINES, COMPOSITIONS, AND METHODS RELATED THERETO
    Publication number: 20230143228
    Abstract: This disclosure relates to methods of promoting immune responses against coronavirus, such as SARS-CoV-2, and compositions related thereto. In certain embodiments, this disclosure relates to methods of vaccinating for coronavirus comprising administering to the subject a composition disclosed herein. In certain embodiments, the composition comprises a recombinant virus such as recombinant MVA that encodes a coronavirus spike protein. In certain embodiments, the coronavirus spike protein comprises a proline mutation at position 986. In certain embodiments, the coronavirus spike protein comprises a proline mutation at position 987.
    Type: Application
    Filed: April 21, 2021
    Publication date: May 11, 2023
    Inventors: Rama Rao AMARA, Sailaja GANGADHARA, Nanda Kishore ROUTHU
  • MONOCLONAL ANTIBODY FOR CORONAVIRUS SPIKE PROTEIN, AND USE THEREOF
    Publication number: 20230391854
    Abstract: Provided are an antibody or an antigen-binding fragment for a coronavirus S protein, a nucleic acid encoding the antibody or the antigen-binding fragment, a host cell comprising the nucleic acid, and a method for preparing the antibody or the antigen-binding fragment. Also provided is a use of the antibody or the antigen-binding fragment in prevention, treatment, and/or diagnosis of coronavirus.
    Type: Application
    Filed: September 9, 2021
    Publication date: December 7, 2023
    Inventors: Jia ZOU, Li LI, Shuaixiang ZHOU, Jianxing HE
  • CHIMERIC RSV AND CORONAVIRUS PROTEINS, IMMUNOGENIC COMPOSITIONS, AND METHODS OF USE
    Publication number: 20230248815
    Abstract: The invention relates generally to chimeric viral fusion proteins comprising the ectodomain and optionally the transmembrane domain of a first viral fusion protein (e.g., a spike protein of a coronavirus) and the cytoplasmic domain of a second viral fusion protein (e.g. RSV), immunogenic compositions comprising such chimeric proteins, and methods of use of same.
    Type: Application
    Filed: June 17, 2021
    Publication date: August 10, 2023
    Inventors: Martin Moore, Robert Jordan, Mariana Tioni
  • ANTIBODIES TO SARS-CORONAVIRUS (COVID-19) S1 SPIKE PROTEIN
    Publication number: 20210388065
    Abstract: The present invention provides recombinant monoclonal antibodies that bind to the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2 or COVID-19) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to SARS-CoV-2 spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing SARS-CoV-2 activity, thus providing a means of treating or preventing COVID-19 infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the SARS-CoV-2 spike protein for use in treating COVID-19 infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the SARS-CoV-2 spike protein.
    Type: Application
    Filed: April 15, 2020
    Publication date: December 16, 2021
    Applicants: ACTIVE MOTIF SHANGHAI LIMITED, SHANGHAI PUBLIC HEALTH CLINICAL CENTER, FUDAN UNIVERSITY, SHANGHAI PUBLIC HEALTH CLINICAL CENTER
    Inventors: Yanan LU, Fei LAN, Jianqing XU, Xi ZHAO, Longfei DING, Yongheng WANG, Jinkai WAN, Shenghui XING, Joseph FERNANDEZ
  • EXPRESSION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) SPIKE PROTEIN SEQUENCES IN PLANTS AND PLANT PRODUCED VACCINE FOR SAME
    Publication number: 20230002780
    Abstract: A plant produced vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is provided where the Spike protein of the virus is expressed in a plant by introducing into a plant a construct comprising a promoter preferentially directing expression to seed of said plant, a nucleic acid encoding the Spike protein and a nucleic acid targeting expression to the endoplasmic reticulum of the plant. The plant expresses the 51 polypeptide at levels of at least 10 mg/kg of seed of said plant. When orally administered to an animal, a protective response is observed including a serum antibody response.
    Type: Application
    Filed: June 24, 2022
    Publication date: January 5, 2023
    Inventors: John Howard, Erin Egelkrout
  • MONOCLONAL ANITBODY FOR SPIKE PROTEIN OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS AND USE THEREOF
    Publication number: 20210355193
    Abstract: The present invention relates to monoclonal antibodies for a spike protein of the Middle East respiratory syndrome coronavirus (MERS-CoV), and a use thereof. Particularly, monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the Si domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV. Also, the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV, and the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV. Further, the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.
    Type: Application
    Filed: August 23, 2018
    Publication date: November 18, 2021
    Inventors: Hansaem Lee, Janghoon Choi, Sungsoon Kim, Lingshu Wang, Barney Graham, John Mascola
  • MONOCLONAL ANTIBODY FOR SPIKE PROTEIN OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS, AND USE THEREOF
    Publication number: 20230265169
    Abstract: The present invention relates to monoclonal antibodies for a spike protein of the Middle East respiratory syndrome coronavirus (MERS-CoV), and a use thereof. Particularly, monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the S1 domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV. Also, the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV, and the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV. Further, the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.
    Type: Application
    Filed: September 25, 2022
    Publication date: August 24, 2023
    Inventors: Hansaem Lee, Janghoon Choi, Sungsoon Kim, Lingshu Wang, Barney Graham, John R Mascola
  • COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST CORONAVIRUS
    Publication number: 20230263882
    Abstract: Disclosed herein are CpG-amphiphiles and corona virus antigens (e.g., a coronavirus spike protein, a peptide thereof, or a nucleic acid sequence encoding the same) for use in inducing an immune response in a subject, and methods of administering CpG-amphiphiles and coronavirus antigens (e.g., a coronavirus spike protein, a peptide thereof, a coronavirus nucleocapsid protein, a peptide thereof, or a nucleic acid sequence encoding the same) to induce an immune response in a subject.
    Type: Application
    Filed: June 25, 2021
    Publication date: August 24, 2023
    Inventors: Martin P. STEINBUCK, Lochana M. SEENAPPA, Peter C. DEMUTH, Christopher M. HAQQ, Lisa MCNEIL
Narrow Results

Filter by US Classification